Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks by Keene, CM, Cassidy, T, Zhao, Y, Griesel, R, Jackson, A, Sayed, K, Omar, Z, Hill, A, Ngwenya, O, Van Zyl, G, Flowers, T, Goemaere, E, Maartens, G, Meintjes, G

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial by Zhao, Y, Keene, C, Griesel, R, Sayed, K, Gcwabe, Z, Jackson, A, Ngwenya, O, Schutz, C, Goliath, R, Cassidy, T, Goemaere, E, Hill, A, Maartens, G, Meintjes, G

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen by Keene, CM, Griesel, R, Zhao, Y, Gcwabe, Z, Sayed, K, Hill, A, Cassidy, T, Ngwenya, O, Jackson, A, van Zyl, G, Schutz, C, Goliath, R, Flowers, T, Goemaere, E, Wiesner, L, Simmons, B, Maartens, G, Meintjes, G